Shanghai Henlius Biotech Inc. Obtains EU GMP Certificates for HLX11 and HLX14 Production Lines

Reuters
02 Jul
<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> Inc. Obtains EU GMP Certificates for HLX11 and HLX14 Production Lines

Shanghai Henlius Biotech Inc. has announced that its wholly-owned subsidiary, Shanghai Henlius Biologics Co., Ltd., has successfully obtained Certificates of GMP Compliance from the Federal Agency for Medicines and Health Products in Belgium. This certification applies to the drug substance and drug product lines for HLX11 and HLX14, indicating that these production lines meet the European Union's Good Manufacturing Practice standards. The approval facilitates the commercial production and distribution of HLX11 and HLX14 within the EU, bolstering the company's global pharmaceutical market presence. This development follows a previous exclusive licensing agreement with Organon LLC for the global commercialization of these products, excluding mainland China, Hong Kong, Macau, and Taiwan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on July 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10